Sunphenon Epigallocatechin-Gallate (EGCg) in Duchenne Muscular Dystrophy
Status:
Completed
Trial end date:
2018-09-06
Target enrollment:
Participant gender:
Summary
The aim of this multicentre, prospective, double blind, placebo controlled, randomized pilot
study is to investigate safety and tolerance of Epigallocatechin-Gallate (EGCG, the major
polyphenol in green tea) in patients with muscular dystrophy of the Duchenne type.
In a second step the investigators want to investigate the effect of EGCG on the course of
the Duchenne condition.